Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of camidanlumab tesirine in relapsed or refractory classical Hodgkin lymphoma
2018-002556-32Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Aug 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camidanlumab tesirine in classical Hodgkin lymphoma (cHL), sponsored by ADC Therapeutics. Primary endpoint: Objective response rate (ORR). Started Aug 2019; status: completed.
02
Drugs
camidanlumab tesirine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2018-002556-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002556-32.